Courtney E Harris
Overview
Explore the profile of Courtney E Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kakoullis L, Alonso C, Burns R, Aleissa M, Haddad E, Kim A, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39873391
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients. Methods:...
2.
Harris C, Gupta S, Sax P, Vilchez G, Schwartz I, Jandhyala D, et al.
Transpl Infect Dis
. 2024 Dec;
27(1):e14420.
PMID: 39692593
Social media provides platforms for transplant infectious diseases (TIDs) clinicians to network, exchange ideas, and educate each other and the broader public. A #TxIDChat on the social media platform X...
3.
Bethi S, Taber D, Andrade E, Mesmar Z, Calimlim I, Harris C
Transpl Infect Dis
. 2024 Dec;
:e14416.
PMID: 39692584
Background: While access and outcomes disparities for African American (AA) kidney transplant recipients are documented, there are limited studies assessing medication access disparities in transplantation. Cytomegalovirus (CMV) causes severe complications...
4.
Gorsline C, Sharma D, Harris C, Hand J, Imlay H, Stohs E, et al.
Transpl Infect Dis
. 2024 Nov;
26(6):e14399.
PMID: 39584489
Solid organ transplant and hematopoietic cell transplant patients face an increased risk of infectious diseases, greater exposure to antibiotics, and heightened risk of multidrug-resistant organisms (MDROs) due to their immunosuppressed...
5.
Gow-Lee V, Abu Saleh O, Harris C, Gile J, Akhiyat N, Chesdachai S
Pathogens
. 2024 Oct;
13(10).
PMID: 39452757
Background: Isavuconazole (ISA) has a favorable side effect profile that makes it attractive for treatment of invasive fungal infections (IFI). It carries FDA approval for invasive aspergillosis and mucormycosis, but...
6.
Harris C, Vaidya V, Lan Z, Klompas M, Rhee C, Baden L, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae367.
PMID: 39077053
Among 495 patients who were immunocompromised and tested positive for SARS-CoV-2, polymerase chain reaction cycle thresholds remained <33 beyond 20 days more frequently in patients with hematologic malignancies, particularly those...
7.
Kumar R, Gorsline C, Rader T, Boucher H, Malinis M, Koff A, et al.
Transpl Infect Dis
. 2024 Jul;
26(4):e14326.
PMID: 38967408
Transplant infectious disease (TID) clinicians are integral to the pre-transplantation evaluation. Pre-transplant evaluations allow clinicians to assess risk factors for latent infections and relevant exposures to potential pathogens, address immunizations,...
8.
Harris C, Englander M, Ansari E
Pediatr Emerg Care
. 2024 May;
40(11):e283.
PMID: 38776439
No abstract available.
9.
Harris C, Kumar R, Haidar G, La Hoz R, Gorsline C
Transpl Infect Dis
. 2024 Feb;
26(2):e14247.
PMID: 38349023
The number of transplant infectious disease (TID) fellowship programs has expanded rapidly in the past 5 years, with the creation of many new programs and the expansion of training tracks...
10.
Gorsline C, Tyler R, Sigler R, Wolfe C, Harris C, Kumar R
Transpl Infect Dis
. 2023 Nov;
25(6):e14172.
PMID: 37937964
Donor-derived infections in solid organ transplantation can be prevented by risk stratification of donors based on available information, and inquiries surrounding possible or diagnosed infection are common questions posed to...